PHARMA LITERATI

Every week of thousands of patent applications are published in India. The patent applications filed by the pharma academic research institutes in India go un-noticed. We publish a list of Indian applications published related to pharma academics. This would provide us an idea about the kind of academic research being carried out in these institutes. For details of these patents, please write back to us at  pharmaliterati@gmail.com Invention Application no Inventors Institute Pulmonary function testing induction jacket 1596/MUM/2014A 1) Dr. Prashant Rajdeep Department of Physiology, The M. S. University of Baroda, Vadodara, Gujarat. Apprentice Spirometer 1597/MUM/2014A 1) Dr. Prashant Rajdeep Department of Physiology, The M. S. University of Baroda, Vadodara, Gujarat. Pharmaceutical composition for the fast relief and treatment of inflammation 1556/MUM/2014A 1) Sha

USFDA recently approved Ixazomib, an antineoplastic agent.  Drug name: Ixazomib Innovator: Millennium Pharms Brand name: Ninlaro® Chemical structure: 1,3,2-dioxaborolane-4,4-diacetic acid, 2-[(1R)-1-[[2-[(2,5dichlorobenzoyl) amino] acetyl]amino]-3-methylbutyl]-5-oxo- Indications: Ninlaro® is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. Dosage form: Capsule; Oral Strengths: 2.3mg; 3mg; 4mg

Institute of Pharmaceutical Education and Research, Pune founded in 1990, is India’s leading institute propagating excellence in the Pharmacy profession. The Institute has evolved out of a much-felt, lack of comprehensive, managerial, task oriented input demanded by the rapidly growing pharmacy profession. I.P.E.R’s Pharmaceutical Management Certificate training programmes are brand new career programme evolved through the merger of practical actual experience, theoretical management principles and case studies in pharmaceutical industries, giving a never before industry orientation and training to Pharmacy education in the country. In the age of the specialist, I.P.E.R.’s tailor-made Pharmaceutical Management certificate courses suits your aptitude and interests and opens the doors for high reward placement opportunities in the Pharma Industry. The courses have been prepared by eminent personalities from pharma industry ensuring that education is relevant to the industry’s needs.

The Indian Pharma fraternity: Brace yourselves for the biggest event of the year: CPhI India-2015 We had earlier posted details about CPhI India-2015 held in Mumbai from 1 - 3 December 2015 at the Bombay Convention and Exhibition Centre on our beloved blog. But just as a refresher, please find the information and the relevant links below!   http://www.cphi.com/india/homepage For all those people who have not yet registered, please move it and register here: https://registration.n200.com/survey/1uptfugr1sk39/register?actioncode=IN7&cid=web_IN_hm_bt_vreg_15

Doctors must prescribe heartburn and acidity pills in lowest possible doses and for shortest time to patients to ward off potential side effects, researchers warn. Called Proton pump inhibitors (PPIs), such common over-the-counter pills like omeprazole, rabeprazole and pantoprazole are taken to alleviate gastric distress from stomach acid. "Proton pump inhibitors are associated with a number of rare but potentially serious adverse effects," wrote Dr Todd C. Lee, internal medicine specialist at McGill University Health Centre in Montreal, Quebec."These uncommon effects become highly relevant when considering the tens of millions of patients who take PPIs worldwide," he added. Some PPIs have been associated, in observational studies, with increased risk of heart attack in patients taking the antiplatelet agent called clopidogrel. Other adverse effects, which occur in varying frequencies, include rebound heartburn after discontinuing PPIs, malabsorption o

Pfizer and IIT-Delhi on Tuesday said they have launched an incubation accelerator initiative at the later's campus for Indian startup companies as well as individuals. Christened "The Pfizer IIT-Delhi Innovation and IP Program ", it comprises two components. For innovators seeking comprehensive support to translate their healthcare ideas into patents, the programme will provide two years of residential incubation at IIT-Delhi, funding of up to Rs.50 lakh for each innovator, mentoring support from IIT-Delhi's faculty, access to infrastructure and prototyping laboratories, IP search and filing services, guidance from Pfizer's global experts, and access to venture capitalists and other industry linkages. For innovators who already have a ready proof of concept and are seeking to obtain a patent, the programme will provide access to IP attorneys and services and cover the patent fee. The programme will invite two rounds of proposals during 2015-2016

Every week of thousands of patent applications are published in India. The  patent applications filed by the pharma academic research institutes in India  go un-noticed. We publish a list of Indian applications published related to pharma academics. This would provide us an idea about the kind of academic research being carried out in these institutes. For details of these patents, please write back to us at  pharmaliterati@gmail.com Invention Application No Inventors Institute Granular composition prepared using food grade saponins 2645/MUM/2014A 1) Dr. Vinita Kale 2) Kalyan Jayant Wagh 3) Dr. Abhay M. Ittadwar Gurunanak College of Pharmacy, Nagpur Combinatorial therapeutic regimen of antidiabetic with antihypertensive drugs 3783/MUM/2014A 1) Mr. Gokul A. Khairnar 2) Mr. Pritam B. Patil 3) Dr. Vinod J. Mokale 4) Dr. Jitendra B. Naik North Maharashtra Uni

2015 had already surpassed 2014 as the year with the biggest healthcare deals by value. Now, it's not even close. "Through this combination, Pfizer will have greater financial flexibility that will facilitate our continued discovery and development of new innovative medicines for patients, direct return of capital to shareholders, and continued investment in the United States, while also enabling our pursuit of business development opportunities on a more competitive footing within our industry," said Pfizer chief Ian Read in a statement. The makers of some of the best-selling pharmaceutical products in the world, including Viagra and Botox, are planning to join forces in an agreement that's bound to raise scrutiny from the White House and federal regulators. The Treasury Department announced last week that it would be releasing new rules to make it more difficult for pharma companies to pursue these precise types of domicile-shifting inversion mergers.

Global R&D Summit 2015, a two-day integrated conference, exhibition and award function will be a magnanimous milieu of local and global experts and institutions from industry, academia, government, bilateral/ multilateral agencies, funding organisations and associated establishments that constitute the technology-based start-up ecosystem. Location:                       Vigyan Bhavan, New Delhi. Dates:                             7 - 8 December, 2015 Organizers:                     FICCI and Department of Science & Technology, Government of India. Details:                           http://www.ficcirndsummit.com/e-brochure.pdf

About the conference: Drug Design is the inventive process of finding new therapeutics based on the knowledge of a biological target. The Phrase “Drug Design” to some extent is a misnomer, where Ligand. Design can be a more accurate scientific expression. When a new compound shows promise, its structure can be subjected to physicochemical modification with the aim to optimize its ability to target the intended site. Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery. It includes pre-clinical research (microorganisms/animals), clinical trials (humans) and steps to obtain regulatory approval for commercialization. A Good Pharmacy Practice (GPP) is "the practice of pharmacy that responds to the needs of the people who use the pharmacists’ services to provide optimal, evidence-based care. To support this practice it is essential that there must be an established nationa

In an unusual move AstraZeneca and Sanofi will exchange 210,000 compounds in order to boost their libraries and help launch more drug discovery programmes. The companies have selected the compounds to exchange based on differences from those in their own libraries. Each company will receive sufficient quantities to enable high throughput screening for several years to determine whether they are active against specific biological targets AZ and Sanofi will also share chemical structures and synthetic procedures to facilitate the use of the compounds. Each company can investigate the compounds it receives without restrictions on disease areas. “This is a highly innovative agreement which speaks to our open innovation approach,” said Mene Pangalos, executive vice president of innovative medicines and early development at AstraZeneca.  “We’ve worked hard to enrich our compound library in recent years and this exchange, which is by far the largest we have achieved, enables us

Ahmedabad-based Zydus Cadila is launching an anti-diabetic drug, teneligliptin, at an aggressive price of Rs 7 per day, almost 1/6th the price at which the established gliptins by MNCs are sold . The company said the pricing of the "breakthrough' drug, Tenglyn, is aimed at "making it affordable and accessible to diabetic patients". The drug is priced one-third of the price charged by other domestic companies, including Glenmark Pharma and Ajanta, which are selling the same drug, teneligliptin, for around Rs 20 for a day's therapy. Experts say with competition, prices of these drugs could come down later, but as of now companies are "waiting and watching" the development. Teneligliptin, a third-generation new oral anti-diabetic drug, was first launched by Glenmark in June, priced aggressively at nearly Rs 20 for a day's therapy (Rs 7,263 per year). As against this, all gliptins being sold in the market are priced around Rs 45 for a day'

Who Health Organization is celebrating the first World Antibiotic Awareness Week from 16 to 22 November 2015. The campaign aims to increase awareness of global antibiotic resistance and to encourage best practices among the general public, health workers and policy makers to avoid the further emergence and spread of antibiotic resistance.  Details available at: http://www.who.int/mediacentre/events/2015/world-antibiotic-awareness-week/en/ Further readings on antibiotics on Pharma literati blog: 1. Research Reveals How Antibiotics Work http://pharmaliterati.blogspot.in/2015/11/research-reveals-how-antibiotics-work.html 2. India is the World's antibiotic popping capital http://pharmaliterati.blogspot.in/2015/09/india-is-worlds-antibiotic-popping.html